Endocrine Practice最新文献

{"title":"Re: Early postoperative intact parathyroid hormone dynamics after curative parathyroidectomy for sporadic primary hyperparathyroidism: trajectories, predictors of eucalcemic PTH elevation, and 18-month outcomes.","authors":"Ahmad Alam","doi":"10.1016/j.eprac.2026.09.112","DOIUrl":"https://doi.org/10.1016/j.eprac.2026.09.112","url":null,"abstract":"","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149105297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Info for Readers/Subscription page","authors":"","doi":"10.1016/S1530-891X(26)01126-2","DOIUrl":"10.1016/S1530-891X(26)01126-2","url":null,"abstract":"","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"32 10","pages":"Pages A1-A2"},"PeriodicalIF":4.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149072047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Algorithms to Adaptive Clinical Intelligence in Diabetes Care","authors":"Salvatore Corrao MD","doi":"10.1016/j.eprac.2026.05.006","DOIUrl":"10.1016/j.eprac.2026.05.006","url":null,"abstract":"","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"32 10","pages":"Pages 1595-1597"},"PeriodicalIF":4.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147927669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Nocturnal Cortisol and Catecholamines in the Pathophysiology of Nondipping Blood Pressure in Type 1 Diabetes Mellitus","authors":"Muhammad Mohid Haroon MBBS","doi":"10.1016/j.eprac.2026.05.013","DOIUrl":"10.1016/j.eprac.2026.05.013","url":null,"abstract":"","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"32 10","pages":"Page 1599"},"PeriodicalIF":4.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147971309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Continuous Glucose Monitoring for Postkidney Transplantation in Patients With Pre-existing Type 2 Diabetes","authors":"Dania Salih Bacha MD,&nbsp;Huijun Xiao MS,&nbsp;Kelly Paulus,&nbsp;Diana Isaacs PharmD,&nbsp;Kevin Malloy PharmD,&nbsp;Mona Gossman MD,&nbsp;Alvin Wee MD,&nbsp;M. Cecilia Lansang MD, MPH","doi":"10.1016/j.eprac.2026.05.018","DOIUrl":"10.1016/j.eprac.2026.05.018","url":null,"abstract":"<div><h3>Background</h3><div>Kidney transplantation poses glycemic control challenges for type 2 diabetes mellitus due to immunosuppressive therapy and metabolic changes. In this pilot study, we aimed to assess glucometrics achieved with a continuous glucose monitor (CGM)-based insulin titration protocol during prednisone taper postkidney transplant.</div></div><div><h3>Methods</h3><div>Kidney transplant recipients with pre-existing type 2 diabetes mellitus on insulin therapy were enrolled. CGM metrics were used to adjust insulin dose for 3 months. Data up to 6 months were included. CGM metrics, insulin and prednisone doses, kidney function, and clinical outcomes were analyzed.</div></div><div><h3>Results</h3><div>Time in range increased from 44.2% to 60.8% at 3 months (<em>P</em> = .005) and 72.9% at 6 months (<em>P</em> &lt; .001). TBR 54-69 mg/dL was 0.3% baseline, 0.4% at 3 months (<em>P</em> = .11) and 0.6% at 6 months (<em>P</em> = .036), whereas TBR &lt;54 mg/dL was 0% at baseline with no significant increase at 3 and 6 months. Average glucose decreased from 194.7 mg/dL to 160.6 mg/dL at 3 months and 148.0 mg/dL at 6 months (<em>P</em> &lt; .001). The estimated mean total insulin dose per kg body weight was 0.48 units/kg at baseline, 0.66 units/kg at 3 months, and 0.56 units/kg at 6 months.</div></div><div><h3>Conclusion</h3><div>These findings may assist with better insulin dosing for programs that have similar patient demographics and prednisone taper.</div></div>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"32 10","pages":"Pages 1483-1487"},"PeriodicalIF":4.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147981081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reproductive Considerations in Females With Cystic Fibrosis","authors":"Marissa S. Weiss MD, MSCE,&nbsp;Jennifer M. Chin MD, MS,&nbsp;Sheila K. Mody MD, MPH,&nbsp;Andrea H. Roe MD, MPH","doi":"10.1016/j.eprac.2026.04.021","DOIUrl":"10.1016/j.eprac.2026.04.021","url":null,"abstract":"<div><h3>Objective</h3><div>To synthesize current evidence on fertility, pregnancy outcomes, and contraceptive safety in females with cystic fibrosis (CF) in order to support patient-centered family planning decisions for CF care teams.</div></div><div><h3>Methods</h3><div>Narrative review of the literature addressing female reproductive health in CF, encompassing anatomical, hormonal, and functional contributors to fertility; assisted reproductive technology (ART) outcomes; the impact of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy; pregnancy risks and monitoring; and contraceptive considerations.</div></div><div><h3>Results</h3><div>Infertility has historically affected approximately 37% of females with CF (FwCF) who attempt conception—more than twice the general population rate—driven by mechanisms including altered cervical mucus, ovulatory dysfunction, and impaired uterine pH. Despite this, FwCF who pursue ART achieve clinical pregnancy and live birth rates comparable to age-matched controls. Since FDA approval of elexacaftor/tezacaftor/ivacaftor in 2019, pregnancy rates among FwCF have more than doubled. Pregnancy carries elevated risks of preterm delivery, low birth weight, and gestational diabetes, particularly among those with prepregnancy FEV1 &lt;50%. Approximately 50% of pregnancies in FwCF are unintended, underscoring the need for tailored contraceptive counseling that accounts for drug interactions with CF medications and thromboembolism risk in those with implanted ports.</div></div><div><h3>Conclusion</h3><div>Female reproductive health in CF is shaped by disease-specific mechanisms that historically reduced fertility, though ART outcomes are comparable to the general population and CFTR modulator therapy has substantially improved pregnancy rates. Pregnancy in FwCF requires careful risk stratification and monitoring. Given the high rate of unintended pregnancy, proactive and individualized contraceptive counseling is an essential component of comprehensive CF care.</div></div>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"32 10","pages":"Pages 1575-1582"},"PeriodicalIF":4.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147986811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Updates in Cystic Fibrosis–Related Diabetes (CFRD)","authors":"Henry Zelada MD,&nbsp;Katie L. Kaput DO,&nbsp;Shauna Runchey MD,&nbsp;Trang N. Le MD","doi":"10.1016/j.eprac.2026.05.038","DOIUrl":"10.1016/j.eprac.2026.05.038","url":null,"abstract":"<div><div>Cystic fibrosis–related diabetes is a unique form of diabetes caused by a combination of exocrine and endocrine pancreatic dysfunction. These changes lead to early problems with insulin secretion, disrupted communication within the islets, and an abnormal glucagon response. As a result, people develop a pattern of glucose abnormalities that is different from both type 1 and type 2 diabetes, often showing postmeal hyperglycemia and unpredictable fluctuations. Diagnosis still relies mainly on the oral glucose tolerance test, but continuous glucose monitoring is becoming increasingly helpful, especially for detecting early or intermittent dysglycemia in daily life. The introduction of highly effective cystic fibrosis transmembrane conductance regulator modulators has dramatically improved survival, lung health, and growth, yet it has also shifted the metabolic profile of adults with cystic fibrosis. Many are now experiencing greater weight gain, increased adiposity, and more insulin resistance. Insulin therapy remains the cornerstone of treatment because it improves nutrition, lung function, and overall clinical outcomes. Modern insulin delivery technologies, including hybrid automated systems, may help selected patients by reducing glucose variability and better supporting individual routines. There is also growing interest in the cautious use of certain noninsulin medications for specific adult phenotypes, although the evidence is still limited. As this population continues to age and live healthier lives, the management of cystic fibrosis–related diabetes will need to become more personalized, with careful attention to changing nutritional status, evolving insulin needs, and long-term health goals.</div></div>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"32 10","pages":"Pages 1583-1589"},"PeriodicalIF":4.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148210529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlating Menstrual Cycles and Cystic Fibrosis Symptoms in the Era of Highly Effective Modulators: Findings of the MENSTRUAL Study","authors":"Sandy Sufian PhD,&nbsp;Alan Schwartz PhD,&nbsp;Elinor Langfelder-Schwind MS,&nbsp;Sheila Mody MD,&nbsp;Molly Ruben MPH,&nbsp;Patricia Walker MD,&nbsp;Georgia Brown MA,&nbsp;Yi-Fan Chen PhD,&nbsp;Emily M. Godfrey MD","doi":"10.1016/j.eprac.2026.05.027","DOIUrl":"10.1016/j.eprac.2026.05.027","url":null,"abstract":"<div><h3>Objectives</h3><div>Chronic disease symptoms fluctuate across the menstrual cycle, but such patterning is understudied in cystic fibrosis (CF), particularly in the post–cystic fibrosis transmembrane conductance regulator modulator (CFTRm) era. This study examined how CF symptoms change across the cycle, identifying which symptoms worsen, how severe they get, and when they occur.</div></div><div><h3>Methods</h3><div>Menstruating cisgender women with CF (ages 18-45) completed surveys and tracked 40 CF and menstrual symptoms daily using a customized app. We assessed symptom periodicity over a 28-day cycle using a cumulative link mixed-effects model and evaluated the effects of CFTRm use and cycle phase, while adjusting for multiple covariates. We interviewed 20 participants using a constructivist grounded theory approach.</div></div><div><h3>Results</h3><div>Sixty-four participants (89%) contributed 3 cycles of symptom data; most (87%) used CFTRm and reported mild symptoms. Across multiple statistical models, menstrual cycle phase significantly affected CF symptoms, including gastrointestinal symptoms (eg, bloating, gas, stomachache, and bowel movement pain) and pulmonary/sinus symptoms (eg, coughing up mucus, migraine, and runny, stuffy nose). A phase effect on CF symptoms remains even after adjusting for CFTRm use. Qualitative findings corroborate these patterns, with interviewees reporting improvements in coughing, coughing mucus, and joint pain with CFTRm, though some experienced intensified gastrointestinal symptoms.</div></div><div><h3>Conclusions</h3><div>CF symptom severity varied across the menstrual cycle, even after accounting for CFTRm. While menstruation was associated with the highest symptom burden, other cycle phases showed significantly reduced symptom severity, which varies by symptom. Clinicians should encourage females with CF to track symptoms to support phasic CF management strategies.</div></div>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"32 10","pages":"Pages 1555-1566"},"PeriodicalIF":4.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148239153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Postoperative Intact Parathyroid Hormone Dynamics After Curative Parathyroidectomy for Sporadic Primary Hyperparathyroidism: Trajectories, Predictors of Eucalcemic PTH Elevation, and 18-Month Outcomes","authors":"Vivek Jha MD,&nbsp;Sanjay Kumar Bhadada DM,&nbsp;Soham Mukherjee DM,&nbsp;Rimesh Pal DM,&nbsp;Amal Shaharyar MD,&nbsp;Divya Dahiya MCh","doi":"10.1016/j.eprac.2026.04.019","DOIUrl":"10.1016/j.eprac.2026.04.019","url":null,"abstract":"<div><h3>Objective</h3><div>Eucalcemic postoperative parathyroid hormone elevation (PePTH) after curative parathyroidectomy for sporadic primary hyperparathyroidism is common, yet its temporal profile and clinical significance remain unclear. Transient hypoparathyroidism also occurs after surgery, but the immediate course of intact PTH (iPTH) recovery is poorly defined. We therefore characterized day-by-day postoperative calcium, phosphate, and iPTH trajectories through postoperative day (POD) 5 and evaluated preoperative predictors of PePTH at 6 months and 18-month biochemical outcomes.</div></div><div><h3>Methods</h3><div>In this prospective cohort study, 58 adults with sporadic primary hyperparathyroidism underwent curative minimally invasive parathyroidectomy with intraoperative PTH confirmation of cure and were followed for 18 months. Albumin-corrected calcium, phosphate, and iPTH were measured preoperatively; at 6 h; daily through POD5; and at 3, 6, 12, and 18 months. Three-variable model (iPTH, estimated glomerular filtration rate (eGFR), and beta-C-terminal telopeptide of type I collagen (β-CTX)) assessed via Firth logistic regression and AUROC.</div></div><div><h3>Results</h3><div>IPTH reached a nadir at 6 h (median 12.1 pg/mL), re-entered the reference range by POD2, and stabilized by POD5, remaining similar at 3 months. Calcium normalized within 48 h, whereas phosphate rose from POD2 and stabilized by 3 months. PePTH occurred in 13/58 patients (22%). Higher baseline iPTH, lower eGFR, and higher β-CTX independently predicted PePTH (AUROC 0.81). During 18-month follow-up, biochemical recurrence occurred in 6/13 patients (46%) with PePTH and in 0/45 patients with normalized iPTH.</div></div><div><h3>Conclusion</h3><div>After curative parathyroidectomy, higher baseline iPTH, β-CTX, and lower eGFR identified patients at increased risk of PePTH at 6 months. PePTH was associated with biochemical recurrence through 18 months and may identify higher-risk postoperative phenotype requiring closer follow-up.</div></div>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"32 10","pages":"Pages 1497-1504"},"PeriodicalIF":4.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147981140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is the Etoposide, Doxorubicin, and Cisplatin Plus Mitotane Regimen Able to Prolong Survival in Patients With Metastatic Adrenocortical Carcinoma?","authors":"Alfredo Berruti MD,&nbsp;Deborah Cosentini MD,&nbsp;Marta Laganà MD,&nbsp;Salvatore Grisanti MD, PhD","doi":"10.1016/j.eprac.2026.05.009","DOIUrl":"10.1016/j.eprac.2026.05.009","url":null,"abstract":"","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"32 10","pages":"Pages 1592-1594"},"PeriodicalIF":4.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147927594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}